Redeye comments on Faron announcing an agreement with Parexel to support the randomized phase IIb BEXERA trial of bexmarilimab in treatment-naïve higher-risk MDS. The 90-patient, double-blind study will evaluate two dose levels of bexmarilimab in combination with azacitidine versus placebo, aiming to select the recommended phase III dose and generate randomized efficacy data ahead of registrational development. We view the appointment of a global CRO with hematology expertise as an encouraging operational milestone that signals progress toward trial initiation.
LÄS MER
